Cognoa and the University of Missouri Test CanvasDx
The University of Missouri School of Medicine, in collaboration with the company Cognoa, has conducted a study on the application of an artificial intelligence-integrated diagnostic tool known as CanvasDx. The innovation is designed to assist primary care physicians in assessing children for autism spectrum disorder.
This FDA-approved device analyzes patient data through its algorithms to provide a predictive outcome regarding a potential diagnosis. CanvasDx aims to function as a supportive diagnostic tool within general practice settings and could potentially serve regions lacking immediate access to specialist care.
The research focused on the device’s implementation within an established telehealth training network for clinicians. The study found that CanvasDx yielded determinate results for approximately half of the study participants without producing incorrect positive or negative classifications, and notably did not conflict with the final diagnoses made by the evaluating physicians.
Image Credit: University of Missouri School of Medicine